School of Chemical and Biomolecular Engineering, The University of Sydney, Sydney, 2006, Australia.
Orthopaedic Research & Biotechnology Unit, The Children's Hospital at Westmead, Westmead, 2145, Australia.
Macromol Biosci. 2018 Dec;18(12):e1800201. doi: 10.1002/mabi.201800201. Epub 2018 Nov 5.
The manufacture of a biocompatible carrier for controlled delivery of bioactive compounds is described. This carrier is composed of a mesoporous silica nanoparticle as core that is homogenously distributed in an injectable hydrogel. For the synthesis of nanoparticles, a one step sol-gel method is developed to produce pores with the range of 100 nm. BMP2 and Fluorescein-conjugated bovine serum albumin is used as proteinaceous agents for measuring release, and is loaded into mesoporous silica nanoparticles at the optimum conditions of 48 h incubation period using 1:10 ratio of protein to nanoparticles. The release of proteins from either mesoporous nanoparticles or hydrogel individually involves a burst release stage, however the release from the core/shell carrier designed in this study follows a zero order kinetic. In summary, this biomaterial may be favorable for delivery of bioactive compounds such as BMP2 for a range of applications including bone tissue regeneration.
一种用于生物活性化合物控制释放的生物相容载体的制备方法。该载体由介孔硅纳米颗粒作为核组成,均匀分布在可注射水凝胶中。为了合成纳米颗粒,开发了一种一步溶胶-凝胶法来产生 100nm 范围内的孔。BMP2 和荧光素结合牛血清白蛋白被用作测量释放的蛋白质制剂,并在 48 小时孵育期内使用 1:10 的蛋白与纳米颗粒的比例装入介孔硅纳米颗粒中。蛋白质从介孔纳米颗粒或水凝胶中单独释放都涉及到突释阶段,但是本研究设计的核/壳载体的释放遵循零级动力学。总之,这种生物材料可能有利于递送生物活性化合物,如 BMP2,可用于包括骨组织再生在内的一系列应用。